The U.S. Centers for Medicare and Medicaid ruled after the close Thursday that it will fully cover Dendreon Corp.'s (DNDN) Provenge, a treatment for advanced prostate cancer. The stock is now trading higher by 0.91 on 443K shares.
Dendreon Corp. gapped up at the open Thursday, but steadily declined during the first hour of trade. The stock finished down by 1.06 at $39.44 on above average volume.
For comments and feedback: editorial@rttnews.com